Cystatin C vs creatinine: Which better reflects kidney aging?

Q: Which marker is more accurate for measuring kidney function?

Cystatin C alone is often less biased by muscle mass than creatinine alone, and the combined CKD-EPI equation (creatinine + cystatin C) is usually the strongest routine non-invasive estimate when both markers are available. Measured GFR with iohexol or inulin clearance is still more accurate, but it is rarely used outside research, transplant, or high-stakes clinical workups.

Q: Can creatinine be normal but kidney function actually be poor?

Yes — this is exactly the sarcopenia trap. In older adults and people with low muscle mass, creatinine can sit squarely in the "normal" range while measured GFR is already 40–50 mL/min/1.73m². Cystatin C or the combined equation uncovers these cases.

Q: How often should I retest kidney markers?

For healthy adults under 50 with no risk factors, once every 1–2 years alongside your longevity blood panel is reasonable. For adults over 60, or anyone with hypertension, diabetes, cardiovascular disease, or a first-degree relative with kidney disease, annual testing is recommended. If a marker is abnormal, retest within 2–4 weeks and then on your physician's schedule.

Q: Does creatine supplementation affect these tests?

Yes — creatine monohydrate can raise serum creatinine by 10–30% without changing real kidney function. If you supplement, pause for at least 7 days before testing, or use cystatin C (which is unaffected) for accurate tracking.

Q: Is cystatin C worth the extra cost?

For a healthy 35-year-old with average body composition, probably not. For anyone over 60, any strength athlete, anyone with sarcopenia, or anyone whose creatinine-based eGFR sits between 55 and 75, it's one of the highest-value add-ons to a basic blood panel. ---

In a landmark 2013 analysis published in The New England Journal of Medicine, Shlipak and colleagues pooled data from more than 90,000 adults and reached a conclusion that reshaped how nephrologists and longevity researchers think about kidney markers: cystatin C-based eGFR predicts all-cause mortality and cardiovascular events more accurately than creatinine-based eGFR — and the difference is largest precisely in people whose creatinine “looks normal.”

When both markers are reported together, the cystatin C vs eGFRcr-cys guide explains when to trust the combined estimate.

Imagine you open your latest lab report. Creatinine: 1.05 mg/dL (93 µmol/L). eGFR: 85 mL/min/1.73m². Everything is flagged green. Your doctor nods and moves on. But are your kidneys really aging at a healthy pace — or is a protein-based marker you’ve never heard of hiding a very different story?

This article gives you the head-to-head comparison you need: what creatinine and cystatin C actually measure, why muscle mass makes creatinine a biased longevity marker, and when it’s worth asking your physician for a cystatin C test.

If your specific lab pattern is cystatin C high with normal creatinine, start there first; the interpretation is less about picking a winner and more about resolving a discordant kidney signal.

What you’ll learn:

Why cystatin C is less biased by muscle mass than creatinine
How the CKD-EPI 2021 equations differ for creatinine, cystatin C, and the combined formula
Who benefits most from adding cystatin C to their blood panel
How to interpret discordant results and what to do next

Quick answer

Cystatin C is less biased by muscle mass, diet, and hydration than creatinine, and in most large prospective cohorts it is a stronger predictor of all-cause mortality, cardiovascular events, and progression to end-stage kidney disease. Creatinine remains cheaper, universally available, and perfectly adequate for healthy middle-aged adults with average body composition. The combined CKD-EPI creatinine + cystatin C equation currently offers the most accurate eGFR estimate and is the preferred option when the two single-marker results disagree or when muscle mass is unusual (sarcopenia, bodybuilding, amputation, paralysis).

Key facts

Creatinine -> muscle bias: creatinine reflects both kidney filtration and creatinine production from muscle, diet, supplements, and some drugs.
Cystatin C -> muscle-independent context: cystatin C is less affected by muscle mass, but thyroid status, steroids, inflammation, smoking, and obesity can still shift it.
Combined eGFRcr-cys -> best routine estimate: using both markers usually improves accuracy when the single-marker estimates disagree.
Discordance -> follow-up: a big gap between eGFRcr and eGFRcys should be interpreted with UACR, blood pressure, medication context, and repeat trends.
Body composition -> test choice: cystatin C is most useful when creatinine may be misleading, such as sarcopenia, bodybuilding, amputation, or major weight change.
Biological age -> context matters: kidney markers should be read as a cluster, not as one isolated biological-age input.

What is creatinine?

Creatinine is a waste product of muscle metabolism. Muscle cells continuously convert creatine (and phosphocreatine) into creatinine at a roughly constant rate of about 1.6–1.7% of the total creatine pool per day. The kidneys then filter creatinine out of the blood, with the filtered fraction excreted in urine.

Because production depends on skeletal-muscle mass, serum creatinine reflects two variables at once: how well the kidneys are filtering, and how much muscle you carry. That’s also why normal ranges differ by sex:

Population	Typical serum creatinine
Adult men	0.74–1.35 mg/dL (65–119 µmol/L)
Adult women	0.59–1.04 mg/dL (52–92 µmol/L)

Creatinine is also sensitive to short-term factors your lab doesn’t know about: a large steak the night before, intense resistance training in the previous 24 hours, dehydration, or certain drugs (trimethoprim, cimetidine) can push the number up without any change in true kidney function.

For a deeper dive into why creatinine still matters for longevity, see our companion guide on creatinine as a longevity biomarker. For a head-to-head look at how creatinine and BUN complement each other — and what the BUN/creatinine ratio reveals — see the BUN vs creatinine comparison.

What is cystatin C?

Cystatin C is a small cysteine-protease inhibitor (around 13 kDa) produced at a relatively constant rate by all nucleated cells in the body. It’s freely filtered by the glomerulus and then almost entirely reabsorbed and catabolized by proximal tubular cells, so it essentially doesn’t return to the bloodstream. Serum concentration therefore depends mainly on glomerular filtration.

Typical reference values sit around 0.53–0.95 mg/L in adults, with a mild upward drift after age 60. For the full age-banded reference table, see our guide on cystatin C normal range by age. Cystatin C is reported in mg/L everywhere — there is no alternative unit to remember.

Why longevity researchers care about it:

Muscle-independent. Body composition changes, sarcopenia, and athletic muscle mass have only minor effects.
Earlier detection. Cystatin C rises with modest declines in GFR that creatinine still misses — the so-called “creatinine-blind range” between 60 and 90 mL/min/1.73m².
Stronger mortality signal. In multiple cohorts (Cardiovascular Health Study, MESA, HUNT2), higher cystatin C tracks with cardiovascular events and all-cause mortality more tightly than creatinine, even in people labeled “CKD-free” by creatinine alone.

Cystatin C is not perfect. It’s modestly influenced by thyroid status, systemic corticosteroid use, high inflammation, and obesity — but none of these come close to the muscle-mass distortion that plagues creatinine.

Why creatinine can mislead — especially in muscular or sarcopenic people

The central weakness of creatinine is that “normal” depends on how much muscle you have.

False reassurance in sarcopenia

Consider a 78-year-old woman with advanced age-related muscle loss. Her creatinine comes back at 0.7 mg/dL (62 µmol/L) — smack in the middle of the female reference range. The CKD-EPI creatinine equation estimates her eGFR at 82 mL/min/1.73m². On paper, her kidneys look fine. But repeat the calculation with cystatin C (1.6 mg/L) and her eGFR drops to 45 mL/min/1.73m² — stage G3a chronic kidney disease. The creatinine was low because she has almost no muscle mass left to produce it, not because her kidneys filter well.

This “sarcopenia trap” is one of the most underappreciated reasons older adults are under-diagnosed with CKD.

False alarms in muscular athletes

The opposite happens in strength athletes and bodybuilders. A 32-year-old man who squats 180 kg and weighs 95 kg of mostly lean mass can routinely show creatinine around 1.3–1.4 mg/dL (115–124 µmol/L). CKD-EPI creatinine would suggest an eGFR of 65 — borderline stage G2 CKD, triggering unnecessary worry. This creatinine high but eGFR normal pattern is a distinct, common scenario with its own interpretation logic. Cystatin C in the same athlete is usually well within normal (around 0.8 mg/L), and combined-equation eGFR lands comfortably above 90.

Diet and drugs

A heavy meat meal can raise creatinine by 10–30% for up to 12 hours, because ingested creatine is partly converted to creatinine. Creatine monohydrate supplementation has a similar but more sustained effect. Some medications (trimethoprim, cimetidine, fenofibrate) block tubular secretion of creatinine and bump serum levels without any true GFR change. None of these confound cystatin C.

Head-to-head comparison

Feature	Creatinine	Cystatin C
Source	Muscle breakdown	All nucleated cells
Production rate	Variable (muscle mass, diet, exercise)	Relatively constant
Typical adult range	M: 0.74–1.35 mg/dL · F: 0.59–1.04 mg/dL (52–119 µmol/L)	0.53–0.95 mg/L (both sexes)
Sensitivity in early CKD (GFR 60–90)	Low — “creatinine-blind range”	High — detects earlier
Affected by muscle mass	Yes, strongly	Minimally
Affected by diet	Yes (high-meat meals, creatine)	No
Affected by hydration	Yes (short-term swings)	Minor
Other biases	Drugs blocking tubular secretion	Thyroid status, steroids, high CRP
Sex-specific reference range	Yes	No
Predictive value for all-cause mortality	Moderate	Stronger in most cohorts
Predictive value for cardiovascular events	Moderate	Stronger
Cost per test	Low (often ≤ $10)	Higher (often $20–60)
Availability	Universal — in every basic panel	Requires specific request in most labs
Use in PhenoAge algorithm	Yes	No

The takeaway: for biological-age tracking in people with unusual body composition or in older adults, cystatin C adds information that creatinine simply cannot provide.

Interpreting eGFR equations that use each marker

Modern nephrology uses the CKD-EPI 2021 equations developed by Inker and colleagues and endorsed by KDIGO. There are three versions, and knowing which one your lab used changes interpretation.

CKD-EPI 2021 creatinine

The default equation in most North American and European labs after the 2021 race-free update. Inputs: serum creatinine, age, sex. Output: eGFRcr in mL/min/1.73m². Accurate enough for population screening in healthy adults but inherits every muscle-mass bias described above.

CKD-EPI 2021 cystatin C

Inputs: serum cystatin C and age (no sex, no race). Output: eGFRcys. Useful as a confirmatory test when creatinine-based eGFR is suspected to be biased. It isn’t perfect on its own — small fluctuations in cystatin C production can shift the number — which is why guidelines rarely rely on cystatin C alone.

CKD-EPI 2021 creatinine + cystatin C (combined)

This is the equation to remember. By combining both markers, eGFRcr-cys usually performs better than either marker alone because creatinine and cystatin C have different sources of bias. KDIGO 2024 recommends using the combined estimate when cystatin C is available, especially when accuracy matters or creatinine may be biased.

The two single-marker eGFRs disagree by more than ~15 mL/min/1.73m²
A decision on dialysis initiation, kidney donation, or dose-adjustment of a critical drug (chemotherapy, DOACs) depends on the result
Body composition is atypical (sarcopenia, obesity, amputation, spinal-cord injury, bodybuilding)
The patient is an older adult in whom kidney aging trajectories matter for longevity

If your lab reports only eGFRcr, you can manually plug the same serum values into the NKF online CKD-EPI 2021 calculator — it’s free and takes 30 seconds.

When to ask for cystatin C testing

Cystatin C isn’t needed for everyone. Consider requesting it when any of the following applies:

You’re an older adult with visible muscle loss (grip strength below age-specific norms, recent unintentional weight loss, functional decline). Creatinine almost certainly overestimates your kidney function.
You’re a resistance-trained athlete or bodybuilder with “borderline” creatinine-based eGFR (55–75) and no other risk factors. Cystatin C typically reassures.
Discordant results — for example, a rising creatinine with stable urea and stable albuminuria, or a creatinine-based eGFR that drops after you start a new workout program.
You’re monitoring biological-age-relevant decline and want a muscle-independent trend line. Cystatin C is the better year-on-year tracker. If you’re unsure whether your eGFR slope is normal or accelerated, establish that baseline first — then use cystatin C to confirm it.
A critical clinical decision depends on eGFR accuracy: chemotherapy dose, kidney donation workup, or eligibility for drugs contraindicated below a specific GFR.
You have diabetes, hypertension, or known cardiovascular disease and want to catch early CKD inside the creatinine-blind 60–90 window.

Cost is the main practical barrier. In the United States cystatin C runs $20–60 out of pocket; in many European national systems it’s covered when there’s a documented clinical reason (sarcopenia, athletic body composition, or discordant findings). One measurement every 1–3 years is usually enough for tracking, unless your physician asks otherwise.

What to do with an abnormal result

An unexpected cystatin C or creatinine value is rarely a reason to panic, but it is a reason to act methodically.

Don’t decide on one lab. Any single kidney marker should be repeated before you draw conclusions. Recheck in 2–4 weeks under fasting, well-hydrated conditions, with no intense exercise the day before and no high-meat meal the night before.
Rule out acute causes. Severe dehydration, recent contrast imaging, a new NSAID, a new ACE-inhibitor or SGLT2 inhibitor, heart failure decompensation, or urinary obstruction can all cause transient changes. Review the last 4–8 weeks honestly.
Add urine albumin-to-creatinine ratio (UACR). Kidney damage has two dimensions: filtration (eGFR) and leakage (albuminuria). A UACR above 30 mg/g confirms kidney injury even if eGFR is still normal — and it’s one of the first markers to change.
Run the combined CKD-EPI equation. If you have both creatinine and cystatin C, use the combined formula and note the result alongside the single-marker values.
Book a medical consultation. Persistent eGFR < 60 for ≥ 3 months, UACR ≥ 30 mg/g, a sharp drop from your personal baseline, or a repeated high cystatin C with normal creatinine pattern all warrant a visit with your primary-care physician or nephrologist. Bring trajectories, not just the latest number.
Recheck your longevity panel. Kidney markers rarely move in isolation. Review them alongside the rest of a proper longevity blood panel — fasting glucose, HbA1c, urate, CRP, and lipids — to see the full metabolic context.

How SuperAge uses kidney markers in biological age

SuperAge computes your biological age using the PhenoAge algorithm and other validated models. PhenoAge, developed by Levine et al., uses serum creatinine as one of its nine input biomarkers — it does not use cystatin C directly. You can read the full breakdown of how the score is calculated in our guide to PhenoAge and the KDM biological age from blood, or in the broader overview of how SuperAge calculates biological age.

Because SuperAge knows creatinine’s weakness, the app does something most blood-panel tools don’t: it contextualizes your creatinine with body-composition data from HealthKit. If your lean mass is in the bottom quartile for your age and sex, the app flags your creatinine-based eGFR as potentially overestimated and suggests discussing cystatin C with your physician. If your lean mass is in the top quartile and your creatinine looks “borderline,” the app flags the opposite risk — false alarm — rather than treating the number at face value.

If you add a cystatin C value manually, SuperAge recomputes eGFR using the CKD-EPI 2021 combined equation and uses that estimate in your kidney sub-score. The goal is straightforward: your biological age shouldn’t be skewed by how much muscle you happen to carry.

Frequently asked questions

Which marker is more accurate for measuring kidney function?

Cystatin C alone is often less biased by muscle mass than creatinine alone, and the combined CKD-EPI equation (creatinine + cystatin C) is usually the strongest routine non-invasive estimate when both markers are available. Measured GFR with iohexol or inulin clearance is still more accurate, but it is rarely used outside research, transplant, or high-stakes clinical workups.

Can creatinine be normal but kidney function actually be poor?

Yes — this is exactly the sarcopenia trap. In older adults and people with low muscle mass, creatinine can sit squarely in the “normal” range while measured GFR is already 40–50 mL/min/1.73m². Cystatin C or the combined equation uncovers these cases.

How often should I retest kidney markers?

For healthy adults under 50 with no risk factors, once every 1–2 years alongside your longevity blood panel is reasonable. For adults over 60, or anyone with hypertension, diabetes, cardiovascular disease, or a first-degree relative with kidney disease, annual testing is recommended. If a marker is abnormal, retest within 2–4 weeks and then on your physician’s schedule.

Does creatine supplementation affect these tests?

Yes — creatine monohydrate can raise serum creatinine by 10–30% without changing real kidney function. If you supplement, pause for at least 7 days before testing, or use cystatin C (which is unaffected) for accurate tracking.

Is cystatin C worth the extra cost?

For a healthy 35-year-old with average body composition, probably not. For anyone over 60, any strength athlete, anyone with sarcopenia, or anyone whose creatinine-based eGFR sits between 55 and 75, it’s one of the highest-value add-ons to a basic blood panel.

Key takeaways

Creatinine measures muscle-turnover plus kidney filtration; cystatin C measures mostly kidney filtration.
Creatinine is cheap, universal, and fine for average-body-composition adults — but biased by muscle mass, diet, and hydration.
Cystatin C catches early CKD that hides in the creatinine-blind range (eGFR 60–90) and predicts mortality and cardiovascular events more accurately in most cohorts.
The combined CKD-EPI 2021 creatinine + cystatin C equation is often the strongest routine non-invasive eGFR estimate when both markers are available.
Ask for cystatin C if you’re older with low muscle mass, a resistance-trained athlete, or facing a critical decision that depends on eGFR accuracy.
An abnormal result calls for repeat testing, a UACR, and a conversation with your physician — not panic.

This article is for educational purposes only and does not replace professional medical advice. If you have abnormal kidney markers, consult your healthcare provider before making any changes.

Start tracking the kidney markers that actually matter

SuperAge reads creatinine from your blood panel, contextualizes it with body-composition data from HealthKit, and — when you add a cystatin C value — recomputes your eGFR using the CKD-EPI 2021 combined equation. The result is a kidney sub-score that doesn’t lie to you just because you lift weights or happen to be over 70.

Download SuperAge on the App Store and start tracking the biomarkers that actually reflect your kidney aging.

References

Inker, L. A., Eneanya, N. D., Coresh, J., Tighiouart, H., Wang, D., Sang, Y., et al. (2021). New creatinine- and cystatin C-based equations to estimate GFR without race. New England Journal of Medicine, 385(19), 1737-1749. DOI
Shlipak, M. G., Matsushita, K., Arnlov, J., Inker, L. A., Katz, R., Polkinghorne, K. R., et al. (2013). Cystatin C versus creatinine in determining risk based on kidney function. New England Journal of Medicine, 369(10), 932-943. DOI
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. (2024). KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International, 105(4S), S117-S314. DOI
Stevens, L. A., Coresh, J., Schmid, C. H., Feldman, H. I., Froissart, M., Kusek, J., et al. (2008). Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. American Journal of Kidney Diseases, 51(3), 395-406. DOI
Levine, M. E., Lu, A. T., Quach, A., Chen, B. H., Assimes, T. L., Bandinelli, S., et al. (2018). An epigenetic biomarker of aging for lifespan and healthspan. Aging, 10(4), 573-591. DOI

Track kidney markers in context — not in isolation — and your biological-age trajectory becomes a much more honest mirror of how you’re really aging.